论文部分内容阅读
目的分析经肝动脉化疗栓塞术(TACE)联合单药口服希罗达治疗结直肠癌肝转移的疗效及不良反应。方法一线化疗失败的非手术结直肠癌肝转移患者30例,随机均分为两组:试验组经TACE 3周后予以希罗达口服化疗,停药1周后评价疗效;对照组给予标准mFOLFOX6/FOLFIRI方案化疗,2个周期后予以评价疗效。比较两组近期疗效和不良反应。结果两组均无完全缓解病例,试验组部分缓解(PR)4例,疾病稳定(SD)6例、疾病进展(PD)5例,对照组PR 3例、SD 6例、PD 6例。试验组年平均住院日少于对照组[(56.27±2.19)d vs.(85.33±2.52)d](P<0.05);试验组肝功能损害、发热、腹痛和手足综合征发生比例高于对照组(P<0.05),但白细胞及血小板减少发生比例低于对照组(P<0.05)。结论 TACE联合希罗达治疗结直肠癌肝转移患者有一定疗效,能缩短年均住院时间,不良反应少。
Objective To analyze the curative effect and adverse reactions of transcatheter arterial chemoembolization (TACE) combined with single oral oral Xeloda in the treatment of liver metastases of colorectal cancer. Methods Thirty patients with non-operative colorectal cancer with liver metastasis who failed in first-line chemotherapy were randomly divided into two groups: the experimental group received Xeloda oral chemotherapy 3 weeks after TACE, and the efficacy was evaluated after 1 week of withdrawal. The control group was given standard mFOLFOX6 / FOLFIRI regimen chemotherapy, to evaluate the efficacy after 2 cycles. The two groups compared the short-term efficacy and adverse reactions. Results There was no complete remission in both groups. There were 4 cases of partial remission (PR), 6 cases of stable disease (SD), 5 cases of disease progression (PD), 3 cases of PR, 6 cases of PD and 6 cases of PD in the control group. The average length of hospital stay in the experimental group was less than that in the control group [(56.27 ± 2.19) d vs. (85.33 ± 2.52) d] (P <0.05). The incidence of liver dysfunction, fever, abdominal pain and hand-foot syndrome in the experimental group was higher than that in the control group (P <0.05), but the incidence of white blood cells and thrombocytopenia was lower than that of the control group (P <0.05). Conclusion TACE combined with Xeloda in the treatment of colorectal cancer patients with liver metastases have a certain effect, can shorten the average length of hospital stay, fewer adverse reactions.